Effect of OPC Factor on Energy Levels

November 16, 2011 updated by: University of Pennsylvania

The Effect of OPC Factor on Energy Levels in Healthy Individuals Aged 45-65: A Randomized Controlled Trial

In this study the food supplement OPC Factor will be tested to determine its effectiveness for increasing energy levels in healthy people aged 45-65 when compared to a placebo. All subjects will receive both active product and placebo at some time during the study. The study is nine weeks in duration. It involves three visits, taking an effervescent powder in water twice a day, and answering 24 multiple choice questions once a week. Subjects who complete the study can elect to receive a two month supply of the study product free of charge.

Study Overview

Status

Completed

Conditions

Detailed Description

OPC Factor, a food supplement which contains grape seed extract, pine bark extract,vitamins and minerals, has shown during clinical observation the effect of raising energy levels in people aged 45-65. It is believed that the mechanism of action is based on enhanced production of ATP by mitochondria.

In this study subjects will be assigned by chance to either the active product group or the placebo group. Subjects will take the product for three weeks. Then there will be a two week wash out period followed by subjects being crossed over to the other group for a three week period. Subjects, assessors, and health providers will be masked as to who is in the active product group and who is in the placebo group. Subjects will meet with the primary investigator three times during the study, will fill out very short questions once a week, and receive phone calls once a week from study personnel.

This study is a randomized, placebo controlled, triple-blinded, cross-over study that tests the hypothesis that OPC Factor produces a response rate of 70% in the active product phase versus a 30% response rate during the placebo phase. A response is defined as at least a 20% absolute increase on the Energy subscale of the Activation-Deactivation Adjective Check List.

Study Type

Interventional

Enrollment (Actual)

27

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Penn Presbyterian Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. 45 to 65 years of age at the time of recruitment
  2. Healthy -- see exclusion criteria
  3. There is the possibility of at least a 20% absolute increase in the subject's energy subscale score of the Activation-Deactivation Adjective Checklist (AD ACL). For the purpose of meeting the inclusion criteria, the subject fills out the AD ACL with the following instructions: "Each of the words below describes feelings or moods. Please circle the rating next to each word that best describes your feelings during the past month. These instructions are different from the instructions used when the study endpoints are being measured so as to be consistent with the way the questionnaire was validated."

Exclusion Criteria:

  1. Any major medical or mental illness (including a history of bipolar disorder, borderline personality disorder, and schizophrenia)
  2. Medical diseases known to be associated with fatigue but not limited to:

    • AIDS
    • Anemia
    • Cancer or history of cancer (excluding basal cell carcinoma of the skin)
    • Chronic fatigue syndrome
    • Congestive heart failure
    • Chronic obstructive pulmonary disease (COPD)
    • Depression
    • Diabetes
    • Drug/alcohol dependence
    • Fibromyalgia
    • Hypertension that is uncontrolled or difficult to control
    • Hypothyroidism
  3. Subjects taking the following medical therapies:

    • Beta-blocking medications
    • Human growth hormone
    • Testosterone
    • Warfarin
  4. Subjects taking the following complementary and alternative medicine (CAM) products:

    • Feverfew
    • Garlic supplements
    • Ginseng
    • Red clover
  5. Women who have not gone through menopause - those women who have had one or more menstrual periods in the 12 months prior to the enrollment in the study
  6. The subject's score on the energy subscale of the AD ACL is at a level that precludes at least a 20% absolute increase of that score.
  7. Subjects who are unable to make their own decisions regarding informed consent
  8. Those subjects who have taken any of the medical therapies or CAM products listed but are no longer taking them are eligible to participate provided no other exclusion criteria are present and the subjects have not taken those therapies or products in the six months prior to enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: Placebo
Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
EXPERIMENTAL: OPC Factor(TM)
Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Energy subscore on the Activation-Deactivation Adjective Check List
Time Frame: Nine weeks
Nine weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Four global change questions
Time Frame: Nine weeks
Nine weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Patrick J LaRiccia, MD, University of Pennsylvania

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2006

Primary Completion (ACTUAL)

April 1, 2008

Study Completion (ACTUAL)

April 1, 2008

Study Registration Dates

First Submitted

April 21, 2006

First Submitted That Met QC Criteria

April 21, 2006

First Posted (ESTIMATE)

April 25, 2006

Study Record Updates

Last Update Posted (ESTIMATE)

November 17, 2011

Last Update Submitted That Met QC Criteria

November 16, 2011

Last Verified

November 1, 2011

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 804315

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on OPC Factor(TM)

3
Subscribe